XML 41 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Supplementary Financial Information (Unaudited)
 12 Months Ended
Dec. 31, 2018
Notes to Financial Statements  
Quarterly Financial Information [Text Block]
 
Supplementary Financial Information (Unaudited)
 
Quarterly Results of Operations
 
   
Year Ended December 31, 201
8
  
   
Mar. 31,
201
8
(3)
    
Jun. 30,
201
8
    
Sept. 30,
201
8
    
Dec. 31,
201
8
(4
)
  
   
(in thousands, except per share amounts)
  
Total revenue
   $
60,136
     $
69,814
     $
78,009
     $
86,531
  
Gross profit
    
32,546
      
39,611
      
43,462
      
49,526
  
Net loss
    
(22,991
 )    
(28,464
 )    
(22,665
 )    
(21,631
 )
Basic earnings per share
    
(0.53
 )    
(0.65
 )    
(0.52
 )    
(0.49
 )
Diluted earnings per share
    
(0.53
 )    
(0.65
 )    
(0.52
 )    
(0.49
 )
 
 
   
Year Ended December 31, 201
7
  
   
Mar. 31,
201
7
    
Jun. 30,
201
7
    
Sept. 30,
201
7
(1
)
    
Dec. 31,
201
7
(2
)
  
   
(in thousands, except per share amounts)
  
Total revenue
   $
93,584
     $
84,423
     $
84,511
     $
85,683
  
Gross profit
    
53,513
      
47,835
      
42,071
      
53,084
  
Net income (loss)
    
(11,273
 )    
(14,967
 )    
(48,766
 )    
102
  
Basic earnings per share
    
(0.27
 )    
(0.36
 )    
(1.15
 )    
—
  
Diluted earnings per share
    
(0.27
 )    
(0.36
 )    
(1.15
 )    
—
  
 
 
 
 
(
1
)
The Company abandoned a project related to certain developed technology and in-process research and development from the ClariPhy acquisition which resulted to an impairment charge of
$47,014.
 
 
(
2
)
The benefit for income taxes included revaluation of deferred tax liabilities to the new federal tax rate of
21%
and tax benefit from intercompany transfer of intellectual property rights.
 
 
(
3
)
The benefit for income taxes included partial release of federal valuation allowance resulting from the transfer of an acquired in-process research and development to developed technology in
2018
which allowed the related deferred tax liability to be considered a source of income for realizing deferred tax assets, as well as the revaluation of the foreign deferred tax liability on the in-process research and development based on the foreign tax rates applicable to the anticipated reversal periods.
 
 
(
4
)
The Company recorded a charge of
$7,000
due to impairment of a non-marketable equity investment.